<!DOCTYPE html><html><head><link href='https://fonts.googleapis.com/css?family=Spectral' rel='stylesheet'><style>body {    font-family: 'Spectral';font-size: 14px;}</style></head><body><b>Search Term: </b>"Parkinson's" AND ("gene therapy" OR "genome editing" OR "mRNA therapy")<br><b>Date run: </b>2020/01/02<br><br><h2>PubMed Articles</h2> <br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31822676">Monkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease.</a></b><br><b>Journal:</b> Nat Commun<br><b>Two-year IF:</b> 11.80<br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31676756">Autophagy is inhibited by ubiquitin ligase activity in the nervous system.</a></b><br><b>Journal:</b> Nat Commun<br><b>Two-year IF:</b> 11.80<br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31762963">Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: an ISEV position paper arising from the ISEV membranes and EVs workshop.</a></b><br><b>Journal:</b> J Extracell Vesicles<br><b>Two-year IF:</b> 10.65<br><br><b><a href="http://google.com">More Results...</a></b><br><br><h2>Companies</h2> <br><br><b><a href="https://www.linkedin.com/company/voyager-therapeutics-inc-/about/">Voyager Therapeutics, Inc.</a></b><br><br><b><a href="https://www.linkedin.com/company/debere-capital-partners/about/">DeBere Capital Partners</a></b><br><br><b><a href="https://www.linkedin.com/company/pharmacompany-inc/about/">PharmaCompany, Inc</a></b><br><br><b><a href="http://google.com">More Results...</a></b><br><br><h2>Patents</h2> <br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=(%22Parkinsons%22+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS="Parkinsons"+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=("Parkinsons"+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">Compositions for oral drug administration</a></b><br><b>Patent date:</b> December 24, 2019<br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=2&p=1&f=G&l=50&d=PTXT&S1=(%22Parkinsons%22+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS="Parkinsons"+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=("Parkinsons"+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors</a></b><br><b>Patent date:</b> December 10, 2019<br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=3&p=1&f=G&l=50&d=PTXT&S1=(%22Parkinsons%22+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS="Parkinsons"+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=("Parkinsons"+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">In vivo visualization and control of patholigical changes in neural circuits</a></b><br><b>Patent date:</b> November 19, 2019<br><br><b><a href="http://google.com">More Results...</a></b><br><br><br><b><a href="http://google.com">Link to Full Search Results</a></b><br><body><html>